ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 94 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.15 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $506,085 | +51753.0% | 95,308 | -6.9% | 0.03% | -44.8% |
| Q2 2023 | $976 | -35.1% | 102,413 | -25.1% | 0.06% | -37.0% |
| Q1 2023 | $1,505 | -23.4% | 136,804 | +3.0% | 0.09% | -24.0% |
| Q4 2022 | $1,965 | -99.9% | 132,772 | +47.1% | 0.12% | +7.1% |
| Q3 2022 | $1,725,000 | -12.6% | 90,264 | -2.6% | 0.11% | -7.4% |
| Q2 2022 | $1,974,000 | +17.3% | 92,653 | +6.0% | 0.12% | +37.1% |
| Q1 2022 | $1,683,000 | +24.2% | 87,369 | +33.7% | 0.09% | +32.8% |
| Q4 2021 | $1,355,000 | +85.4% | 65,348 | +113.6% | 0.07% | +76.3% |
| Q3 2021 | $731,000 | +33.2% | 30,596 | +52.1% | 0.04% | +31.0% |
| Q2 2021 | $549,000 | – | 20,119 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $95,526,552 | 6.92% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $33,000 | 4.12% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $6,259,451 | 2.58% |
| Opaleye Management Inc. | 502,000 | $5,522,000 | 1.65% |
| 1492 Capital Management LLC | 223,516 | $2,458,676 | 1.52% |
| MIRABELLA FINANCIAL SERVICES LLP | 45,299 | $9,849,004 | 1.49% |
| Saturn V Capital Management LP | 178,217 | $1,960,387 | 1.46% |
| AlphaCentric Advisors LLC | 190,000 | $2,090,000 | 1.44% |
| Rubric Capital Management LP | 3,500,000 | $38,500,000 | 1.00% |
| MPM BioImpact LLC | 254,137 | $2,795,507 | 0.73% |